Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
Ann S LaCasce, Michelle E Kho, Jonathan W Friedberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
Michael Wang, Yasuhiro Oki, Barbara Pro, et al.
Leukemia & Lymphoma
|
April 11, 2015
Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy
Mani Akhtari, Jay Paul Reddy, Chelsea C Pinnix, et al.
British Journal of Haematology
|
January 7, 2014
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
Yasuhiro Oki, Hubert Chuang, Beth Chasen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
Anas Younes, Barbara Pro, Michael J Robertson, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Cancer
|
December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project
Bouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
British Journal of Haematology
|
October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
Yasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Leukemia & Lymphoma
|
August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
Bei Hu, Anas Younes, Jason R Westin, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
Ann S LaCasce, Michelle E Kho, Jonathan W Friedberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
Michael Wang, Yasuhiro Oki, Barbara Pro, et al.
Leukemia & Lymphoma
|
April 11, 2015
Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy
Mani Akhtari, Jay Paul Reddy, Chelsea C Pinnix, et al.
British Journal of Haematology
|
January 7, 2014
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
Yasuhiro Oki, Hubert Chuang, Beth Chasen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
Anas Younes, Barbara Pro, Michael J Robertson, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Cancer
|
December 11, 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project
Bouthaina S Dabaja, Ann M Vanderplas, Allison L Crosby-Thompson, et al.
British Journal of Haematology
|
October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
Yasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Leukemia & Lymphoma
|
August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
Bei Hu, Anas Younes, Jason R Westin, et al.
Page
of 3